Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
We believe that great teams are made up of people who are happy, fulfilled and have a sense of purpose. Flexibility and work/life balance are highly valued.
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
The disease can affect multiple organs in dogs, causing kidney damage, liver failure, and even death. The most effective prevention method is vaccination.